Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2988 - An open-label, multicenter phase 1b study of radium-223 + paclitaxel in cancer patients with bone metastases

Date

11 Sep 2017

Session

Poster display session

Presenters

Ravit Geva

Authors

R. Geva1, J. Lopez2, S. Danson3, H. Joensuu4, A. Peer5, S.J. Harris6, F. Souza7, B.A. Ploeger8, K.M.C. Pereira9, R. Perets10

Author affiliations

  • 1 Research Unit, Division Of Oncology, Tel Aviv Sourasky Medical Center, 64239 - Tel Aviv/IL
  • 2 Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton/GB
  • 3 Department Of Oncology And Metabolism, Sheffield Experimental Cancer Medicine Centre, Weston Park Hospital, Sheffield/GB
  • 4 Department Of Oncology, Helsinki University Hospital, Helsinki/FI
  • 5 Oncology Division, Rambam Health Care Campus, 31096 - Haifa/IL
  • 6 Department Of Medical Oncology, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton/GB
  • 7 Clinical Pharmacodynamics Expert Oncology, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 8 Drug Discovery, Pharmaceuticals, Clinical Pharmacometrics, Bayer Pharma AG, Berlin/DE
  • 9 Pharmaceuticals Development, Bayer Pharma AG, São Paulo/BR
  • 10 Oncology Division, Rambam Health Care Campus, Haifa/IL
More

Resources

Abstract 2988

Background

Concomitant radium-223 (Ra-223) and chemotherapy is a possible option for cancer patients (pts) with bone metastases (mets). Both treatments impact hematologic parameters, and myelosuppression risk during coadministration is unknown. This phase 1b study (NCT02442063) in cancer pts with bone mets evaluated the safety of Ra-223 + paclitaxel (PTX) and the mode of interaction between treatments regarding myelosuppression.

Methods

Eligible pts had a confirmed malignant solid tumor with ≥ 2 bone mets and were candidates for PTX treatment. Treatment included 7 PTX cycles (90 mg/m2 IV per wk as per local standard of care; 3 wk on/1wk off) combined with 6 Ra‑223 cycles (55 kBq/kg IV; 1 injection every 4 wk, starting at PTX cycle 2). The primary end point was percentage of pts with neutropenia and thrombocytopenia during treatment with Ra‑223 + PTX (cycles 2 and 3) vs PTX alone (cycle 1). A previously developed dose-exposure-response model describing the time course of PTX and Ra-223–induced suppression of absolute neutrophil counts was used to evaluate the mode of interaction (additive or synergistic) between Ra-223 and PTX.

Results

Of 22 enrolled pts, 15 were treated; 13 completed cycles 1-3 and were included in the pharmacodynamics analysis. Tumors in treated pts were breast (7 pts), prostate (4 pts), bladder (1 pt), non‒small cell lung (1 pt), myxofibrosarcoma (1 pt), and neuroendocrine (1 pt). 7 pts had received ≥ 3 prior chemotherapy regimens. In the 13 pts who completed cycle 3, grade 3 neutropenia rates in cycles 2 and 3 were 31% and 8%, respectively, vs 23% in cycle 1; there were no cases of grade 4 neutropenia or grade 3/4 thrombocytopenia. No pts discontinued treatment due to toxicity from the treatment combination. Safety data for the breast cancer pt subset will be presented. The myelosuppression model showed an additive effect of Ra-223 to PTX-induced neutropenia, with an additional 10% average decrease in absolute neutrophil count vs PTX alone.

Conclusions

In pts with solid tumors and bone mets, Ra-223 was well tolerated when combined with PTX, with an additional 10% average decrease in neutrophil levels compared with PTX monotherapy. The combination should be explored further in pts with bone mets.

Clinical trial identification

NCT02442063

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.